The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells

Breast Cancer Research and Treatment

Volumn 150, Issue 2, 2015, Pages 309-320

  Fang, Wei Bin ^a   Yao, Min ^a   Jokar, Iman ^a   Alhakamy, Nabil ^b   Berkland, Cory ^b   Chen, Jin ^c   Brantley Sieders, Dana ^c   Cheng, Nikki ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autophagy; CCL2; Luminal breast cancer; Necrosis; siRNA; TAT cell penetrating peptide

Indexed keywords

CCL2 PROTEIN, HUMAN; MONOCYTE CHEMOTACTIC PROTEIN 1; SMALL INTERFERING RNA;

ANIMAL; AUTOPHAGY; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; MOUSE; NECROSIS; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; AUTOPHAGY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CELL SURVIVAL; CHEMOKINE CCL2; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; MICE; MICE, TRANSGENIC; NECROSIS; RNA, SMALL INTERFERING;

EID: 84925407906     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3324-4     Document Type: Article

References (68)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi:10.1073/pnas.191367098
2. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. doi:10.1093/jnci/djp082
3. Zong Y, Zhu L, Wu J, Chen X, Huang O, Fei X, He J, Chen W, Li Y, Shen K (2014) Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. PLoS One 9(8):e95629. doi:10.1371/journal.pone.0095629
4. Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, Oga A, Nagashima Y, Sasaki K (2012) Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Res Notes 5:376. doi:10.1186/1756-0500-5-376
5. Tran B, Bedard PL (2011) Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 13(6):221. doi:10.1186/bcr2904
6. Li M, Ransohoff RM (2009) The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis. Semin Cancer Biol 19(2):111–115. doi:10.1016/j.semcancer.2008.11.001
7. Bruserud O, Kittang AO (2009) The chemokine system in experimental and clinical hematology. Curr Top Microbiol Immunol 341:3–12. doi:10.1007/82_2010_18
8. Hemmerich S, Paavola C, Bloom A, Bhakta S, Freedman R, Grunberger D, Krstenansky J, Lee S, McCarley D, Mulkins M, Wong B, Pease J, Mizoue L, Mirzadegan T, Polsky I, Thompson K, Handel TM, Jarnagin K (1999) Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. Biochemistry 38(40):13013–13025
9. Han KH, Green SR, Tangirala RK, Tanaka S, Quehenberger O (1999) Role of the first extracellular loop in the functional activation of CCR2. The first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signaling. J Biol Chem 274(45):32055–32062
10. Monteclaro FS, Charo IF (1996) The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J Biol Chem 271(32):19084–19092
11. Zabel BA, Zuniga L, Ohyama T, Allen SJ, Cichy J, Handel TM, Butcher EC (2006) Chemoattractants, extracellular proteases, and the integrated host defense response. Exp Hematol 34(8):1021–1032
12. Zimmermann HW, Tacke F (2011) Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 10(6):509–536
13. Raman D, Sobolik-Delmaire T, Richmond A (2011) Chemokines in health and disease. Exp Cell Res 317(5):575–589. doi:10.1016/j.yexcr.2011.01.005
14. De Paepe B, Creus KK, De Bleecker JL (2008) Chemokines in idiopathic inflammatory myopathies. Front Biosci 13:2548–2577
15. Koelink PJ, Overbeek SA, Braber S, de Kruijf P, Folkerts G, Smit MJ, Kraneveld AD (2009) Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther. doi:10.1016/j.pharmthera.2011.06.008
16. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9(1):R15
17. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6(8):3282–3289
18. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M (2001) Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92(5):1085–1091
19. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, Ochiai A (2009) Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 125(6):1276–1284. doi:10.1002/ijc.24378
20. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355):222–225. doi:10.1038/nature10138
21. Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193(6):727–740
22. Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N (2012) CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem 287(43):36593–36608. doi:10.1074/jbc.M112.365999
23. Fang WB, Jokar I, Chytil A, Moses HL, Abel T, Cheng N (2011) Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression. Clin Exp Metastasis 28(4):351–366. doi:10.1007/s10585-011-9373-0
24. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP (2006) A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 54(8):2387–2392. doi:10.1002/art.21975
25. Makley LN, Gestwicki JE (2013) Expanding the number of ‘druggable’ targets: non-enzymes and protein–protein interactions. Chem Biol Drug Des 81(1):22–32. doi:10.1111/cbdd.12066
26. Liu T, Altman RB (2014) Identifying druggable targets by protein microenvironments matching: application to transcription factors. CPT 3:e93. doi:10.1038/psp.2013.66
27. Vives E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272(25):16010–16017
28. Baoum A, Xie SX, Fakhari A, Berkland C (2009) “Soft” calcium crosslinks enable highly efficient gene transfection using TAT peptide. Pharm Res 26(12):2619–2629. doi:10.1007/s11095-009-9976-1
29. Pickel L, Matsuzuka T, Doi C, Ayuzawa R, Maurya DK, Xie SX, Berkland C, Tamura M (2010) Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol Ther 9(4):277
30. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol 31(2):203–209. doi:10.1200/JCO.2012.43.4134
31. Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS, Ellis IO, Rakha EA (2012) Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 14(1):R3. doi:10.1186/bcr3084
32. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, Flick MJ, Witte DP, Dano K, Degen JL (1998) Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16(24):3097–3104. doi:10.1038/sj.onc.1201869
33. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL (2005) Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 24(32):5053–5068. doi:10.1038/sj.onc.1208685
34. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL (2001) Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 61(22):8298–8305
35. Guy C, Cardiff R, Muller W (1992) Induction of mammary tumors by expression a polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961
36. Hembruff SL, Jokar I, Yang L, Cheng N (2010) Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia 12(5):425–433
37. Graeber TG, Sawyers CL (2005) Cross-species comparisons of cancer signaling. Nat Genet 37(1):7–8. doi:10.1038/ng0105-7
38. Budhu S, Wolchok J, Merghoub T (2014) The importance of animal models in tumor immunity and immunotherapy. Curr Opin Genet Dev 24:46–51. doi:10.1016/j.gde.2013.11.008
39. Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC, Seagroves TN (2012) Hypoxia-inducible factor 1 alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14(1):R6. doi:10.1186/bcr3087
40. Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, Sharpless NE, Perou CM (2013) Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res 19(17):4889–4899. doi:10.1158/1078-0432.CCR-13-0522
41. Pirnia F, Frese S, Gloor B, Hotz MA, Luethi A, Gugger M, Betticher DC, Borner MM (2006) Ex vivo assessment of chemotherapy-induced apoptosis and associated molecular changes in patient tumor samples. Anticancer Res 26(3A):1765–1772
42. Guerriero JL, Ditsworth D, Fan Y, Zhao F, Crawford HC, Zong WX (2008) Chemotherapy induces tumor clearance independent of apoptosis. Cancer Res 68(23):9595–9600. doi:10.1158/0008-5472.CAN-08-2452
43. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894):191–195. doi:10.1038/nature00858
44. Tanida I, Ueno T, Kominami E (2004) LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 36(12):2503–2518. doi:10.1016/j.biocel.2004.05.009
45. Kabakov AE, Kudryavtsev VA, Gabai VL (2011) Determination of cell survival or death. Methods Mol Biol 787:231–244. doi:10.1007/978-1-61779-295-3_17
46. Miller FR (2000) Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5(4):379–391
47. Riaz M, Elstrodt F, Hollestelle A, Dehghan A, Klijn JG, Schutte M (2009) Low-risk susceptibility alleles in 40 human breast cancer cell lines. BMC Cancer 9:236. doi:10.1186/1471-2407-9-236
48. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–527. doi:10.1016/j.ccr.2006.10.008
49. Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de Jong P, Oredsson S, Ringner M, Hoglund M, Borg A (2007) High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosom Cancer 46(6):543–558. doi:10.1002/gcc.20438
50. Loberg RD, Day LL, Harwood J, Ying C, John LNS, Giles R, Neeley CK, Pienta KJ (2006) CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8(7):578–586. doi:10.1593/neo.06280
51. Roca H, Varsos ZS, Pienta KJ (2009) CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia 11(12):1309–1317
52. Roca H, Varsos Z, Pienta KJ (2008) CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem 283(36):25057–25073. doi:10.1074/jbc.M801073200
53. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P (2014) Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 15(2):135–147. doi:10.1038/nrm3737
54. Amaravadi RK, Thompson CB (2007) The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13(24):7271–7279. doi:10.1158/1078-0432.CCR-07-1595
55. Carlomagno C, Perrone F, Lauria R, de Laurentiis M, Gallo C, Morabito A, Pettinato G, Panico L, Bellelli T, Apicella A et al (1995) Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology 52(4):272–277
56. Yu L, Yang W, Cai X, Shi D, Fan Y, Lu H (2010) Centrally necrotizing carcinoma of the breast: clinicopathological analysis of 33 cases indicating its basal-like phenotype and poor prognosis. Histopathology 57(2):193–201. doi:10.1111/j.1365-2559.2010.03601.x
57. Tomes L, Emberley E, Niu Y, Troup S, Pastorek J, Strange K, Harris A, Watson PH (2003) Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 81(1):61–69. doi:10.1023/A:1025476722493
58. Rundqvist H, Johnson RS (2013) Tumour oxygenation: implications for breast cancer prognosis. J Intern Med 274(2):105–112. doi:10.1111/joim.12091
59. Altman BJ, Rathmell JC (2012) Metabolic stress in autophagy and cell death pathways. Cold Spring Harb Perspect Biol 4(9):a008763. doi:10.1101/cshperspect.a008763
60. Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104(8):2224–2234
61. Ahluwalia A, Tarnawski AS (2012) Critical role of hypoxia sensor–HIF-1alpha in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem 19(1):90–97
62. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4:e838. doi:10.1038/cddis.2013.350
63. Khurana B, Goyal AK, Budhiraja A, Arora D, Vyas SP (2010) siRNA delivery using nanocarriers - an efficient tool for gene silencing. Curr Gene Ther 10(2):139–155
64. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25. doi:10.1016/j.addr.2013.11.009
65. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269(14):10444–10450
66. Thoren PE, Persson D, Isakson P, Goksor M, Onfelt A, Norden B (2003) Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem Biophys Res Commun 307(1):100–107
67. Prinetti A, Prioni S, Loberto N, Aureli M, Nocco V, Illuzzi G, Mauri L, Valsecchi M, Chigorno V, Sonnino S (2011) Aberrant glycosphingolipid expression and membrane organization in tumor cells: consequences on tumor-host interactions. Adv Exp Med Biol 705:643–667. doi:10.1007/978-1-4419-7877-6_34
68. Fulda S (2009) Tumor resistance to apoptosis. Int J Cancer 124(3):511–515. doi:10.1002/ijc.24064